Citius Pharmaceuticals (CTXR)
(Delayed Data from NSDQ)
$0.71 USD
0.00 (-0.28%)
Updated May 3, 2024 04:00 PM ET
After-Market: $0.72 +0.02 (2.13%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
CTXR 0.71 0.00(-0.28%)
Will CTXR be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CTXR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CTXR
After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR)
Citius (CTXR) Posts Top-Line Data From Pivotal Lymphoma Study
CTXR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CTXR
Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
Citius Pharmaceuticals to raise $15M through direct offering; shares fall
Citius Pharmaceuticals to sell 21.4M shares at 70c in registered direct offering
12 Health Care Stocks Moving In Thursday's Pre-Market Session